Joe Cabral

Joe is a Partner on the Frazier Life Sciences team and focuses on identifying, evaluating, and creating new ventures.

Joe joined Frazier Life Sciences in 2021, where he focuses on the firm’s private investment and company creation strategies. He has co-led investments and currently serves on the board of multiple private companies still in stealth mode, including two Frazier-founded NewCos. He co-led FLS’ investment in and previously served on the board of Halda Therapeutics (acquired by JnJ). He is currently a board observer at Alpha-9 Oncology and Hillstar Bio. He has contributed to multiple other investments since joining the firm, including NewAmsterdam Pharma via his role as VP, Acquisitions for Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC). 
  
Prior to joining FLS, Joe was in venture creation at Flagship Pioneering and was part of the Generate:Biomedicines founding team, where he held operational roles in protein engineering and strategy. Previously, Joe was an early employee at Moderna working in molecular biology and informatics, where he led research activities in modified RNA biophysics and protein translation, and, helped launch mRNA-4157, a personalized cancer vaccine program. 
  
Joe received his MBA from the Ross School of Business at the University of Michigan, where he received multiple awards recognizing his outstanding performance in entrepreneurship and venture capital. Joe also holds an M.S. in Genomics and B.S. in Biology from the University of Connecticut.